Navigation Links
Immunotherapy in Oncology Drug Pipeline Update 2011
Date:9/7/2011

NEW YORK, Sept. 7, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Immunotherapy in Oncology Drug Pipeline Update 2011

http://www.reportlinker.com/p0284906/Immunotherapy-in-Oncology-Drug-Pipeline-Update-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.

There are today 473 (421) companies plus partners developing 978 (783) cancer immunotherapy drugs in 1959 (1573) developmental projects in cancer. In addition, there are 16 (12) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 333 (334) drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 336 (315) different targets. These targets are further categorized on in the software application by 56 (54) classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath. Figures in brackets are comparative data from last year.

Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser, whether it is a single drug profile or an entire search you want have a report of.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Drug Pipeline Update at a Glance

Investigators

Includes more than 473 (421) principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 978 (783) cancer immunotherapy drugs in development, which have a total of 1959 (1573) developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

Marketed# 45 (39)

Registered# 1 (7)

Pre-registration# 6 (6)

Phase III# 66 (50)

Phase II# 224 (188)

Phase I# 224 (176)

Preclinical# 608 (449)

No Data# 4 (21)

Suspended# 16 (12)

Ceased# 333 (334)

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

Included cancer immunotherapy drugs are also in development for 186 (167) other indications, where of 81 (75) are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets

Identified drugs are linked to more than 336 (315) different targets, divided into 56 (54) classifications of molecular function:

- Acid phosphatase activity

- Antigen binding

- Auxiliary transport protein activity

- B cell receptor activity

- Carboxypeptidase activity

- Catalytic activity

- Cell adhesion molecule activity

- Chaperone activity

- Chemokine activity

- Cofactor binding

- Complement activity

- Cysteine-type peptidase activity

- Cytokine activity

- Defense/immunity protein activity

- DNA binding

- DNA topoisomerase activity

- DNA-directed DNA polymerase activity

- Extracellular ligand-gated ion channel activity

- Extracellular matrix structural constituent

- G-protein coupled receptor activity

- Growth factor activity

- Hormone activity

- Hydrolase activity

- Isomerase activity

- Kinase activity

- Kinase binding

- Kinase regulator activity

- Ligand-dependent nuclear receptor activity

- Ligase activity

- Metallopeptidase activity

- MHC class I receptor activity

- Molecular function unknown

- Oxidoreductase activity

- Peptidase activity

- Peptide hormone

- Protease inhibitor activity

- Protein binding

- Protein serine/threonine kinase activity

- Protein threonine/tyrosine kinase activity

- Protein-tyrosine kinase activity

- Receptor activity

- Receptor binding

- Receptor signaling complex scaffold activity

- RNA-directed DNA polymerase activity

- Serine-type peptidase activity

- Structural constituent of cytoskeleton

- Structural molecule activity

- T cell receptor activity

- Transcription factor activity

- Transcription regulator activity

- Translation regulator activity

- Transmembrane receptor activity

- Transmembrane receptor protein tyrosine kinase activity

- Transporter activity

- Unclassified

- Unknown

Identified targets are categorized into 27 (25) different primary and alternate sub-cellular localizations:

- Apical membrane

- Cell junction

- Cell surface

- Centrosome

- Clathrin-coated vesicle

- Cytoplasm

- Cytoplasmic vesicle

- Cytoskeleton

- Cytosol

- Endoplasmic reticulum

- Endosome

- Extracellular

- Extracellular matrix

- Golgi apparatus

- Immunological synapse

- Integral to membrane

- Lysosome

- Mitochondrion

- n/a

- Nucleolus

- Nucleus

- Perinuclear region

- Perinuclear vesicle

- Plasma membrane

- Secreted

- Secretory granule

- Soluble fraction

Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.

Target Expression Profile

Direct links are provided from inside the application to 339 (282) protein expression profiles of 231 (201) drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:

- 48 different normal tissue types

- 20 different types of cancer

- 47 cell lines

- 12 samples of primary blood cells

Pathway Referals

Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath.

- BioCarta# 211 (200) Pathways

- KEGG# 110 (112) Pathways

- NetPath# 19 (19) Signaling Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism

In total there are 320 (299) different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound

Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & Synonyms

Presentation of drug name and synonyms

Principal Investigator & Partners

Presentation of principal investigator and partners

Target and Molecular Function of Target

Described target(s) is/are presented with:

Official Gene Symbol – Official Gene Name [Species/Homo Sapiens] – Molecular Function

Target Localization

Described target(s) is/are presented with primary and alternate localizations.

Target Expression Profiles

Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:

48 different normal tissue types

20 different types of cancer

47 cell lines

12 samples of primary blood cells

Targeted Pathways

Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.

Mechanism

Drug mechanism of action

Developmental Projects

Summary field of developmental projects for the drug, including indication, developmental stage and status.

Example:

Cancer, myeloma – Phase II Clinical Trial – Active

Cancer, prostate – Phase III Clinical Trial – Ceased

Drug Description

Short introduction to drug

Compound Data

Compound type, Chemical name, CAS Number and molecular weight

Patent Data

Available patent information related to the drug is presented here.

Business & Markets

Collaborations and deals

Approvals and submissions

Analyst comments

Phase III Data

Available Phase III development data, developmental history and scientific data.

Phase II Data

Available Phase II development data, developmental history and scientific data.

Phase I Data

Available Phase I development data, developmental history and scientific data.

Preclinical Data

Available preclinical development data, developmental history and scientific data.

Licensing Information

Availability for licensing

Application Features

Use 13 different parameters, available in drop-down menus, to find and sort among drugs

- Drug status

- Clinical Trial Status

- Principle Investigator

- Partners

- Indication

- Developmental Stage

- Compound Type

- Mechanism

- Target

- Molecular Function of Target

- Target Localization

- Targeted Pathways

- Free text search of entire drug profile contents

Direct linkage from inside the application to related internet resources

- Drug data is linked to search engines like Google and PubMed

- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath

- Direct links to company web pages of principal investigators

Dynamic Report Generator

Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or an entire search you want have a report of.

System Requirements

- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)

- Browser Application (Internet Explorer)

- Internet access (to access related internet resources)

To order this report:

Biological Therapy Industry: Immunotherapy in Oncology Drug Pipeline Update 2011

Biological Therapy Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
4. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
5. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
6. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
9. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
10. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
11. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Ohio , Feb. 4, 2016 For ... Program, or those already participating in the program, the ... often referred to as the , Mega-Guidance , could ... final guidance is published in September 2016. ... Product and Service Marketing , summarizes the Mega-Guidance,s key ...
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
Breaking Medicine Technology:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and ... number of women and men with eating disorders report a history of trauma, ... the development of an eating disorder. , At the 2016 iaedp Symposium, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
Breaking Medicine News(10 mins):